Polen Capital Management LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 1.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,653 shares of the company’s stock after selling 240 shares during the quarter. Novo Nordisk A/S makes up approximately 0.0% of Polen Capital Management LLC’s portfolio, making the stock its 26th largest position. Polen Capital Management LLC’s holdings in Novo Nordisk A/S were worth $714,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently made changes to their positions in NVO. Morgan Stanley lifted its position in shares of Novo Nordisk A/S by 1.1% in the first quarter. Morgan Stanley now owns 1,450,229 shares of the company’s stock worth $49,714,000 after purchasing an additional 15,086 shares in the last quarter. Cabot Wealth Management Inc. lifted its position in shares of Novo Nordisk A/S by 3.9% in the first quarter. Cabot Wealth Management Inc. now owns 108,656 shares of the company’s stock worth $3,725,000 after purchasing an additional 4,066 shares in the last quarter. Wayne Hummer Investments L.L.C. purchased a new stake in shares of Novo Nordisk A/S in the first quarter worth approximately $209,000. Willingdon Wealth Management raised its position in Novo Nordisk A/S by 3.0% during the second quarter. Willingdon Wealth Management now owns 45,316 shares of the company’s stock valued at $1,944,000 after acquiring an additional 1,325 shares in the last quarter. Finally, Marshall Wace North America L.P. bought a new position in Novo Nordisk A/S during the first quarter valued at approximately $17,406,000. Institutional investors own 6.01% of the company’s stock.
WARNING: This report was first published by BBNS and is the sole property of of BBNS. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://baseballnewssource.com/markets/polen-capital-management-llc-has-714000-position-in-novo-nordisk-as-nvo/1603344.html.
Several brokerages recently weighed in on NVO. BidaskClub raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, June 15th. Zacks Investment Research lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, September 18th. Finally, Bank of America Corporation raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, September 6th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. Novo Nordisk A/S has an average rating of “Hold” and an average price target of $55.00.
Shares of Novo Nordisk A/S (NYSE NVO) opened at 49.22 on Friday. The firm has a market cap of $122.08 billion, a P/E ratio of 19.89 and a beta of 0.60. The stock has a 50 day moving average of $45.97 and a 200 day moving average of $41.13. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $49.45.
The business also recently announced an annual dividend, which was paid on Tuesday, August 29th. Investors of record on Monday, August 21st were issued a dividend of $0.336 per share. The ex-dividend date of this dividend was Friday, August 18th. This is a boost from Novo Nordisk A/S’s previous annual dividend of $0.33. This represents a yield of 1.07%. Novo Nordisk A/S’s dividend payout ratio is currently 36.44%.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with our FREE daily email newsletter.